Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Operating Leases (2020 - 2025)

Maxcyte (MXCT) has disclosed Operating Leases for 6 consecutive years, with $16.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 3.24% to $16.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.8 million, a 3.24% decrease, with the full-year FY2024 number at $17.2 million, down 4.45% from a year prior.
  • Operating Leases was $16.8 million for Q3 2025 at Maxcyte, down from $17.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $18.0 million in Q4 2023 to a low of $500200.0 in Q3 2021.
  • A 5-year average of $13.9 million and a median of $15.9 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: skyrocketed 2873.17% in 2022, then dropped 4.45% in 2024.
  • Maxcyte's Operating Leases stood at $5.2 million in 2021, then surged by 209.18% to $15.9 million in 2022, then grew by 12.74% to $18.0 million in 2023, then fell by 4.45% to $17.2 million in 2024, then fell by 1.88% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Operating Leases are $16.8 million (Q3 2025), $17.2 million (Q2 2025), and $17.5 million (Q1 2025).